ROCKVILLE, Md., May 8, 2008 (PRIME NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced its first quarter financial results for the three month period ended March 29, 2008. The Company reported a net loss from continuing operations of $6.7 million, or $0.13 per share, compared to a net loss of $13.9 million, or $0.23 per share, for the period ended March 31, 2007. Including results from discontinued operations, Nabi had a net loss of $6.2 million, or $0.12 per share, for the current period compared to a net loss of $11.0 million, or $0.18 per share in the first quarter of 2007.
